Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Furiex Pharmaceuticals, Inc. (FURX)
|
Add to portfolio |
|
|
|
| Price: |
$104.77
| | Metrics |
| OS: |
10.8
|
M
| |
-483
|
% ROE
|
| Market cap: |
$1.13
|
B
| |
|
|
|
Net debt:
|
$19.1
|
M
| |
|
|
|
EV:
|
$1.15
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($45.9)
|
M
| |
|
|
|
EBIT
|
($45.9)
|
M
| |
|
|
| EPS |
($5.06)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 |
| Revenues | 71.0 | 40.5 | 4.5 | 9.0 | 6.3 | 18.4 |
| Revenue growth | 75.3% | 802.2% | -50.0% | 42.3% | -65.7% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.2 |
| Gross profit | 71.0 | 40.5 | 4.5 | 9.0 | 6.0 | 18.3 |
| Gross margin | 100.0% | 100.0% | 100.0% | 99.8% | 95.8% | 99.2% |
| Selling, general and administrative | 12.7 | 11.3 | 8.8 | 8.3 | 2.6 | 1.7 |
| Research and development | 82.7 | 69.5 | 44.2 | 50.1 | 11.8 | 8.1 |
| EBIT | -24.4 | -40.3 | -48.6 | -49.5 | -8.3 | 8.4 |
| EBIT margin | -34.4% | -99.6% | -1081.4% | -551.3% | -131.6% | 45.5% |
| Pre-tax income | -29.3 | -42.9 | -49.0 | -49.5 | -8.3 | 6.8 |
| Income taxes | 0.3 | 0.0 | 0.0 | 0.0 | 0.6 | 0.0 |
| Tax rate | | | | | | 0.0% |
| Earnings from continuing ops | -29.7 | -42.9 | -49.0 | -49.5 | -8.3 | 6.8 |
| Earnings from discontinued ops | | | | 5.1 | | -1.0 |
| Net income | -29.7 | -42.9 | -49.0 | -54.7 | -8.9 | 5.8 |
| Net margin | -41.8% | -105.8% | -1090.9% | -608.5% | -141.5% | 31.6% |
| |
| Diluted EPS | ($2.92) | ($4.29) | ($4.96) | ($5.01) | ($0.84) | $0.69 |
| Shares outstanding (diluted) | 10.1 | 10.0 | 9.9 | 9.9 | 9.9 | 9.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|